The share price of "Pharma first brother" of "Pharma fast reading society" has reached a new record with a market value of more than 400 billion yuan
Time of Update: 2019-10-28
(Sina Medical News) On October 27, Jiangsu Wuzhong Industrial Co., Ltd. issued a notice, and the board of directors recently received a written resignation report submitted by Mr. Wang Xiaogang, President (General Manager) of the company.
Patent war! Sanofi, Zaiyuan and Amgen are breaking up again
Time of Update: 2019-03-01
On February 25, Amgen announced that the jury of Delaware region in the United States had ruled that the claims in Amgen's patent were valid, and rejected Sanofi / zayuan's patent
FDA approved drug administration for prevention of heart disease and stroke
Time of Update: 2017-12-07
[enterprise news of China Pharmaceutical network] recently, epatha (evolocumab), a drug approved by the U.S
Food and drug administration, has become a PCSK9 inhibitor
FDA approval of repatha for prevention of heart disease and stroke
Time of Update: 2017-12-05
Source: Sina medical news on December 5, 2017, recently, epatha (evolocumab) was approved by the U.S
Food and drug administration
The drug became the first
Which new drugs have been approved by FDA in 2015
Time of Update: 2016-01-11
In this year, there are 27 drugs going through the approval process - alecensa, avycaz, bridion, cholbam, corlanor, cotellic, cresemba, daklinza, darzalex, dupliciti, entresto, farydak, genvoya, ibrance, kanuma, lenvima, lonsurf, ninlaro, orkambi, portrazza, praxbind, strensiq, tagrisso, unituxin, viberzi, xuriden, yondelis.
Amgen has reached two deals with more than $3 billion to strengthen its R & D pipeline
Time of Update: 2015-09-22
While acquiring dezima Pharma, a Dutch biotech company, to expand its cardiovascular field, Amgen has also launched cooperation with xencor, a cancer immunotherapy company, covering six antibody projects.
What is the value of new drugs competing for the first market in the world
Time of Update: 2015-09-21
Using data on promotion fees and market share from private providers, researchers at Duke University found that the second drug, if two years behind the first drug, would only gain 34% market share even at the peak of sales.
The price war launched by Amgen repatha in EU is only half of the price in US market
Time of Update: 2015-09-07
The FDA approval of repatha of Amgen and praluent of Sanofi / Zaiyuan marks the beginning of a fierce battle in the field of pcsk drugs.
PCSK9 field: Amgen vs Sanofi, price war is about to be staged
Time of Update: 2015-08-13
First, on July 21, repatha (evolocumab), a PCSK9 inhibitor developed by Amgen, was approved by the European Union, marking the successful birth of the world's first new generation of lipid-lowering drugs.
Market analysis of blood lipid regulating drugs: when did pivastatin, a young generation, resist
Time of Update: 2015-07-20
At present, the global market structure of statins for cholesterol lowering drugs is still known as atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, lovastatin and pivastatin.
Who will dominate the cholesterol market? Amgen or Sanofi
Time of Update: 2015-05-28
Source: on May 28, 2015, two companies, Amgen and Sanofi, have changed the pharmaceutical market by virtue of their own new cholesterol lowering therapy.